AngioDynamics, Inc. shares came under sharp pressure following the release of its fiscal second-quarter 2026 results, as investors reacted to widening losses and cautious forward expectations. Despite steady revenue growth, the medical device maker struggled to translate sales momentum into profitability, triggering a double-digit decline in the stock.

The reaction underscores continued market sensitivity to earnings quality and margin visibility, particularly in the healthcare and medtech space.

Stock Reaction Reflects Earnings Disappointment

AngioDynamics (NASDAQ: ANGO) closed the session down 13.53% at $11.44, marking one of its steepest single-day declines in recent months. The selloff followed the company’s Q2 FY2026 earnings release, which highlighted ongoing operating challenges despite stable top-line performance.

Intraday trading showed heightened volatility, with the stock briefly spiking earlier before reversing sharply lower as investors digested the earnings details.

Revenue Holds Steady, Losses Continue

For the quarter, AngioDynamics reported revenue of approximately $79.4 million, broadly in line with recent quarters and analyst expectations. However, earnings remained under pressure, with the company posting a net loss, extending a trend of negative profitability.

Earnings per share came in at $0.00, outperforming consensus expectations for a loss, but still failing to provide a clear inflection point toward sustainable earnings growth.

Earnings History Shows Volatility, Not Stability

While AngioDynamics has delivered several positive earnings surprises over the past year, the magnitude of those beats has been inconsistent. The company’s earnings history reflects:

• Repeated quarterly losses

• Limited margin expansion

• Sensitivity to operating and restructuring costs

This pattern has weighed on investor confidence, particularly as broader markets increasingly favor companies with clear paths to profitability.

Forward Estimates Signal Cautious Outlook

Analyst forecasts suggest continued pressure in the near term. Consensus estimates point to negative EPS through fiscal 2026, with only modest improvement expected in 2027. Revenue growth is projected to remain in the mid-single-digit range, indicating limited acceleration without strategic or operational changes.

Growth estimates for the current fiscal year remain deeply negative, highlighting the challenge AngioDynamics faces in stabilizing earnings even as sales expand.

What Investors Are Watching Next

Looking ahead, investors will focus on whether AngioDynamics can improve operating leverage and rein in costs while maintaining revenue momentum. Key areas to monitor include execution efficiency, margin recovery, and management’s ability to deliver clearer guidance on the path to profitability.

Until there is stronger evidence of earnings normalization, the stock may remain vulnerable to volatility, particularly around earnings events and broader risk-off shifts in healthcare equities.